Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
82.10    -1.00 (-1.20%)
Bid:
80.50
Ask:
81.10
Spread: 0.60 (0.745%)
Market Cap: £134.60m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Acquisition

21 Mar 2016 07:00

RNS Number : 6687S
Synthomer PLC
21 March 2016
 

21 March 2016

Synthomer Plc

Acquisition of HEXION Performance Adhesives & Coatings

Synthomer plc (LSE:SYNT) ('Synthomer' or the 'Group'), a leading speciality chemicals company, today announces the acquisition of HEXION Performance Adhesives & Coatings ('HEXION PAC'), a business of HEXION Inc., a global chemical company based in Columbus, Ohio in the USA. The total consideration is $226 million (£156 million*) which is being funded from both existing cash resources and utilisation of additional credit facilities. The acquisition is expected to complete during the summer 2016 following receipt of regulatory approvals and satisfaction of other closing conditions.

 

Hexion PAC develops, manufactures and markets a wide array of dispersions, additives, powder coatings and speciality monomers, supplying a global customer base across a broad range of end-use including coatings, adhesives and for building and construction applications. The business employs approximately 750 employees and operates 7 sites across Europe, the USA and Asia. In the year to 31 December 2015, HEXION PAC, generated sales of $370 million and EBITDA of $30 million. At 31 December 2015, HEXION PAC had gross assets of $149 million. It is expected that the acquisition will be earnings enhancing for Synthomer in the first full year. The existing leadership team of Hexion PAC will transfer with the business to Synthomer.

 

The acquisition of HEXION PAC significantly strengthens Synthomer's position in the performance adhesives and coatings market, offering access to new product technologies, customers and markets. HEXION PAC is also highly complementary to Synthomer's existing business both geographically and in the markets in which it operates. Following completion, the Group will have a stronger platform from which to continue its growth aspirations in the Speciality Coatings market. Synthomer expects to achieve approximately $12m of annualised synergies by end 2018 through the integration of HEXION PAC's businesses into the Group. The estimated costs to achieve the synergies are $9m of restructuring costs and $12m of capital costs.

 

The purchase price represents a pre-synergy multiple of 7.5x and a post-synergy multiple of 5.4x and the Group's pro-forma leverage will increase to approximately 1.5x based on the Group's 2015 year-end numbers.

 

Calum MacLean, Chief Executive Officer of Synthomer, said:

 

"The acquisition of HEXION PAC represents a further step forward in our strategy to continue to grow and develop the business. This acquisition strengthens our platform for continued growth in the global dispersions and additives market, and in particular expands our presence in the US and Asia. HEXION PAC has a good performance track record and shares our commitment to innovation and emphasis on strong customer relationships. We look forward to welcoming our new colleagues and integrating the business with Synthomer through the remainder of this year."

 

*Foreign exchange rate for Sterling/US Dollar used is $1.45, being the rate as at 19 March 2016.

- ENDS -

 

Enquiries:

Calum MacLean, Chief Executive Officer

Tel: + 44 (0) 1279 436 211

Stephen Bennett, Chief Financial Officer

Tel: + 44 (0) 1279 775 250

Charles Armitstead, Teneo Strategy

Tel: + 44 (0) 207 240 2484

 

 

Conference call:

 

The Company will hold a conference call for investors and analysts at 0900 BST today:

 

Dial-in number: +44 (0) 207 1928 000 Conference ID: 75382782

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQLLFLAVTIIFIR
Date   Source Headline
10th Oct 202310:26 amRNSHolding(s) in Company
9th Oct 20233:08 pmRNSHolding(s) in Company
9th Oct 20239:44 amRNSHolding(s) in Company
6th Oct 20231:56 pmRNSHolding(s) in Company
6th Oct 20238:53 amRNSHolding(s) in Company
5th Oct 20232:40 pmRNSDirector/PDMR Shareholding
5th Oct 202312:27 pmRNSHolding(s) in Company
2nd Oct 20232:22 pmRNSHolding(s) in Company
28th Sep 20237:00 amRNSAdmission of Nil Paid Rights
27th Sep 20237:00 amRNSDespatch of PALs
26th Sep 20237:00 amRNSCapital Reorganisation
25th Sep 20231:58 pmRNSResults of General Meeting
22nd Sep 20233:21 pmRNSAdditional Listing
7th Sep 20233:44 pmRNSPublication of a Prospectus
7th Sep 20237:00 amRNSRights Issue
7th Sep 20237:00 amRNSHalf-year results
18th Jul 20237:00 amRNSPost-close trading update
12th Jul 20233:17 pmRNSAppointment of Non-Executive Director
28th Jun 202312:37 pmRNSDirector/PDMR Shareholding
28th Jun 202312:36 pmRNSDirector/PDMR Shareholding
22nd Jun 202310:20 amRNSDirector/PDMR Shareholding
16th May 20234:00 pmRNSResult of AGM
16th May 20237:00 amRNSAGM trading update
12th May 20231:08 pmRNSDirector/PDMR Shareholding
12th May 20231:06 pmRNSDirector/PDMR Shareholding
13th Apr 202310:02 amRNSHolding(s) in Company
12th Apr 20235:52 pmRNS2022 Annual Financial Report & Notice of 2023 AGM
11th Apr 20237:00 amRNSDirector/PDMR Shareholding
11th Apr 20237:00 amRNSDirector/PDMR Shareholding
29th Mar 20237:00 amRNSDirector/PDMR Shareholding
29th Mar 20237:00 amRNSDirector/PDMR Shareholding
29th Mar 20237:00 amRNSDirector/PDMR Shareholding
28th Mar 20237:00 amRNSFinal Results
21st Mar 20237:00 amRNSRefinancing
28th Feb 20233:33 pmRNSDisposal
31st Jan 20237:00 amRNSPost-close update for the year ended 31 Dec 2022
11th Jan 202311:30 amRNSResult of General Meeting
16th Dec 202212:12 pmRNSPublication of Circular &Notice of General Meeting
13th Dec 20227:00 amRNSProposed Sale of Laminates, Films & Coated Fabrics
8th Dec 20227:00 amRNSDirector/PDMR Shareholding
30th Nov 20227:00 amRNSBoard changes
29th Nov 202211:16 amRNSOutcome of European Commission investigation
1st Nov 20222:53 pmRNSHolding(s) in Company
27th Oct 202210:27 amRNSHolding(s) in Company
25th Oct 20227:00 amRNSDirector/PDMR Shareholding
25th Oct 20227:00 amRNSDirector/PDMR Shareholding
20th Oct 20227:00 amRNSCovenant relaxation to the end of 2023 agreed
13th Oct 20227:00 amRNSHolding(s) in Company
12th Oct 20227:00 amRNSInvestor Seminar
6th Oct 20227:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.